On May 2, 2024 Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, reported that the Company’s abstract for development of SNAP-CAR NK cells will be featured as a poster presentation at the 2024 American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual Meeting, being held virtually and in-person in Baltimore, MD on May 7-11, 2024 (Press release, Coeptis Therapeutics, MAY 2, 2024, View Source;cell-therapy-asgct-27th-annual-meeting-302134117.html [SID1234642607]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Carrie Stoltzman, Director of Cell Biology at Deverra Therapeutics will be presenting data on behalf of Coeptis regarding the development of the SNAP-CAR NK platform, designed to target multiple antigens and potentially address a wide range of cancers.
"The presentation at ASGCT (Free ASGCT Whitepaper) marks a significant milestone in our endeavor to develop innovative cell therapy platforms for cancer and other diseases," stated Dave Mehalick, President and CEO of Coeptis Therapeutics. "Coeptis is poised to pioneer a first-in-class fully universal targeted cell therapy by combining a highly scalable and cost-effective cell generation platform with universal SNAP-CAR technology. The integration of these two platforms has the potential to revolutionize cancer treatment by offering fully universal, antigen-agnostic targeted cell therapies, without the need for HLA matching. We are excited to continue advancing these groundbreaking technologies toward first-in-human clinical trials."
Presentation Information
Session Title: Thursday Posters: Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies
Session Date/Time: 5/9/2024 12:00:00 PM
Presentation Room: Exhibit Hall
Final Abstract Number: 1325